Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
No Data
KRYS Transcript
Krystal Biotech, Inc. (KRYS) Q4 2025 Earnings Call Transcript
Positive2-17
The earnings call highlights strong financial performance, global market expansion, and strategic pipeline developments. Despite some uncertainties in pricing and compliance, the overall sentiment is positive due to strong revenue growth, operational efficiency, and a well-positioned cash reserve. The Q&A section reinforces this with management's confidence in global demand and strategic focus on pipeline investment. The absence of immediate stock buybacks is offset by the promising outlook on market expansion and product adoption, suggesting a positive stock price movement.
Krystal Biotech, Inc. (KRYS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-12
Krystal Biotech, Inc. (KRYS) Q3 2025 Earnings Call Transcript
Positive11-3
The earnings call reveals robust financial performance with record-high revenue, improved gross margins, and a strong balance sheet. The optimistic guidance for future growth, driven by global expansion and pipeline development, supports a positive outlook. The absence of full-year guidance is a minor concern, but overall, the strategic initiatives and financial health indicate a strong positive impact on the stock price.
Krystal Biotech, Inc. (KRYS) Q2 2025 Earnings Call Transcript
Positive8-4
The earnings call presents a positive outlook with a 95% revenue increase YoY and strong long-term growth prospects. Despite some delays in CF data and patient onboarding, management remains confident in achieving market share goals and maintaining financial stability. The Q&A session reveals productive EU engagements and manageable risks, supporting a positive sentiment. However, some uncertainty remains due to delays and lack of specific guidance, tempering the overall positivity.
KRYS Slides
KRYS Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
